pembrolizumab
Pronunciation: PEM broe LIZ ue mab
Other Name(s): Keytruda®
Apparence: solution
mixed into larger bags of fluids
Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.
Drug Monograph
sep 2025
Eligibility Forms
Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line) Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Pembrolizumab (Adult and Pediatric) - Relapsed cHL Post-Autologous Stem Cell Transplant or ASCT Ineligible Pembrolizumab (Adult Who Failed Prior Brentuximab Vedotin) - Relapsed cHL Post-ASCT or ASCT Ineligible Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma Pembrolizumab - First Line Treatment of MSI-H dMMR Metastatic Colorectal Cancer Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma Pembrolizumab - Previously Treated MSI-H dMMR Advanced Endometrial Cancer Pembrolizumab - In Combination with Lenvatinib for Advanced Endometrial Cancer Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Pembrolizumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer Pembrolizumab - Metastatic Persistent or Recurrent Carcinoma of the Cervix Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma Pembrolizumab - In Combo w Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab - In Combo w Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab Pembrolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer Pembrolizumab (Adult and Pediatric) - Unresectable or Metastatic MSI-H or dMMR Advanced Solid Tumours Pembrolizumab - (Neo)Adjuvant Therapy for Resectable Non-Small Cell Lung Cancer Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV MelanomaPatient Info Sheet
avr 2023
What it is used for
- For treating certain types of cancers such as skin (called melanoma), non-small cell lung, head and neck, renal cell (kidney), colorectal, endometrial, cervical, bladder or urinary tract, breast, esophageal and others. It is also used to treat some types of lymphomas.
- Pembrolizumab is an immunotherapy drug. For more information on immunotherapy, click here.